Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Basket
Checkout
Search
Home
Therapy Area Reports
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
« Previous
Next »
Pages:
1
2
3
4
5
6
7
8
Learn More
Nonalcoholic Steatohepatitis (NASH): KOL Insight Update Bulletin [March 2017]
Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include; expert opinions on the modification of...
Compare
Learn More
Age-Related Macular Degeneration (AMD): Update Bulletin [March 2017]
This edition presents key opinion leader (KOL) views on recent developments in the wet age-related macular degeneration (wet AMD) market. Topics covered include: Regenxbio announcing its Investigational New Drug application...
Compare
Learn More
Type 2 Diabetes Mellitus: Update Bulletin #2 [March 2017]
This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include; the US Food and Drug Administration (FDA) approval of AstraZeneca’s...
Compare
Learn More
Breast Cancer KOL Insight: Update Bulletin [March 2017]
Breast Cancer KOL Insight Update Bulletin #3 [2016]: March 2017 This edition presents KOL views on recent developments in the breast cancer market. Topics include; positive results from two Phase III studies:...
Compare
Learn More
Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2017]
Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include; expert opinions on the 12-week Phase II study data published for Prometic’s PBI-4050 as a...
Compare
Learn More
Ulcerative Colitis: Update Bulletin [March 2017]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Protagonist Therapeutics announcing the...
Compare
Learn More
Multiple Myeloma: Update Bulletin [March 2017]
This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned overall survival (OS)...
Compare
Learn More
Multiple Sclerosis: Update Bulletin [February 2017]
Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the development of...
Compare
Learn More
Rheumatoid Arthritis: Payer Insight Update Bulletin [February 2017]
This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and how this has...
Compare
Learn More
Chronic Lymphocytic Leukaemia: Update Bulletin [February 2017]
Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of data presented at...
Compare
Learn More
Melanoma: Update Bulletin [February 2017]
Gain new KOL insights on the latest events happening in malignant melanoma (MM), including; data from Prima BioMed’s Phase I TACTI-mel clinical trial programme for IMP321, a first-in-class Antigen Presenting Cell...
Compare
Learn More
Hepatitis C: Update Bulletin [February 2017]
Gain new KOL insights on the latest events happening in hepatitis C virus (HCV) treatment landscape, including; Gilead’s fixed-dose combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as a treatment...
Compare
Learn More
Non Small Cell Lung Cancer: Update Bulletin [February 2017]
Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination with...
Compare
Learn More
Multiple Sclerosis - Payer Insight: Update Bulletin [January 2017]
This edition presents payer views on recent developments in the multiple sclerosis (MS) market. Topics include; cost-containment strategies for Zinbryta (daclizumab; AbbVie/Biogen) for the treatment of relapsing forms of...
Compare
Learn More
COPD: Update Bulletin [January 2017]
This edition presents key opinion leader (KOL) views on recent developments in the COPD market. Topics covered include; Novartis’ December 2016 publication of positive results from the CRYSTAL study, which explored...
Compare
Learn More
Prostate Cancer: Update Bulletin [January 2017]
Gain new KOL insights on the latest events happening in prostate cancer (PC). In December 2016, Pfizer and Astellas Pharmaceuticals announced the Phase IV PLATO study, evaluating continued treatment with Xtandi plus...
Compare
« Previous
Next »
Pages:
1
2
3
4
5
6
7
8
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved